Long interspersed element-1 (LINE-1 or L1) retrotransposition continues to affect human genome evolution 1,2 . L1s can retrotranspose in the germline, during early development and in select somatic cells [3] [4] [5] [6] [7] [8] ; however, the host response to L1 retrotransposition remains largely unexplored. Here we show that reporter genes introduced into the genome of various human embryonic carcinoma-derived cell lines (ECs) by L1 retrotransposition are rapidly and efficiently silenced either during or immediately after their integration. Treating ECs with histone deacetylase inhibitors rapidly reverses this silencing, and chromatin immunoprecipitation experiments revealed that reactivation of the reporter gene was correlated with changes in chromatin status at the L1 integration site. Under our assay conditions, rapid silencing was also observed when reporter genes were delivered into ECs by mouse L1s and a zebrafish LINE-2 element, but not when similar reporter genes were delivered into ECs by Moloney murine leukaemia virus or human immunodeficiency virus, suggesting that these integration events are silenced by distinct mechanisms. Finally, we demonstrate that subjecting ECs to culture conditions that promote differentiation attenuates the silencing of reporter genes delivered by L1 retrotransposition, but that differentiation, in itself, is not sufficient to reactivate previously silenced reporter genes. Thus, our data indicate that ECs differ from many differentiated cells in their ability to silence reporter genes delivered by L1 retrotransposition.
Long interspersed element-1 (LINE-1 or L1) retrotransposition continues to affect human genome evolution 1,2 . L1s can retrotranspose in the germline, during early development and in select somatic cells 3-8 ; however, the host response to L1 retrotransposition remains largely unexplored. Here we show that reporter genes introduced into the genome of various human embryonic carcinoma-derived cell lines (ECs) by L1 retrotransposition are rapidly and efficiently silenced either during or immediately after their integration. Treating ECs with histone deacetylase inhibitors rapidly reverses this silencing, and chromatin immunoprecipitation experiments revealed that reactivation of the reporter gene was correlated with changes in chromatin status at the L1 integration site. Under our assay conditions, rapid silencing was also observed when reporter genes were delivered into ECs by mouse L1s and a zebrafish LINE-2 element, but not when similar reporter genes were delivered into ECs by Moloney murine leukaemia virus or human immunodeficiency virus, suggesting that these integration events are silenced by distinct mechanisms. Finally, we demonstrate that subjecting ECs to culture conditions that promote differentiation attenuates the silencing of reporter genes delivered by L1 retrotransposition, but that differentiation, in itself, is not sufficient to reactivate previously silenced reporter genes. Thus, our data indicate that ECs differ from many differentiated cells in their ability to silence reporter genes delivered by L1 retrotransposition.
Human ECs have a transcription profile similar to human embryonic stem cells, and have been used as a model of early human development 9 . Previous studies demonstrated that human L1s are expressed in ECs and human embryonic stem cells 3, 10 . We confirmed these findings by conducting L1 expression analyses in male ECs (NTera2D1, 833KE and 2102Ep) and a female EC (PA-1) that exhibits a restricted ectodermal differentiation pattern ( Fig. 1a ; Supplementary Figs 1, 2a and 2c) .
We next assayed a human L1 element (LRE3) 11 tagged with different indicator cassettes (mneoI, mneoI/ColE1 or mEGFPI) [12] [13] [14] for retrotransposition ( Supplementary Fig. 3 ). An inactive L1 (pJM111/ L1 RP mEGFPI) 13, 14 served as a negative control. LRE3 retrotransposition was readily detected in HeLa cells, but not ECs ( Fig. 1b ; Supplementary Figs 2b and 3). Because these assays rely on reporter-gene expression to detect retrotransposition, the above data indicate that L1 retrotransposition is inhibited in ECs. Alternatively, as observed in some experiments with neural progenitor cells 5, 8 , the indicator cassette delivered by L1 retrotransposition may be silenced in ECs. Thus, we isolated genomic DNA from HeLa and PA-1 cells that were transfected either with pLRE3/mEGFPI or pJM111/L1 RP mEGFPI seven days post-transfection [12] [13] [14] . PCR revealed the unspliced (vector) and spliced (retrotransposition) products in pLRE3/mEGFPItransfected HeLa cells, but only the unspliced product in pJM111/ L1 RP mEGFPI-transfected HeLa cells ( Fig. 1c and Supplementary  Fig. 3 ). We also observed the spliced product in pLRE3/mEGFPItransfected PA-1 cells ( Fig. 1c ), suggesting that the retrotransposed EGFP reporter gene (L1-retro-EGFP) was not expressed from the PA-1 genome.
To dissect the mechanism of L1-retro-EGFP silencing, we transfected cells with pLRE3/mEGFPI. Seven days later, we treated cells with the histone deacetylase inhibitor trichostatin A (TSA) for 14 h ( Fig. 2a ) 5, 8 . Flow cytometry revealed a modest increase in the number of EGFP-positive cells after TSA treatment of HeLa cells (1.3% versus 2.6%; Fig. 2a ). In contrast, we observed a marked increase of L1-retro-EGFP expression after TSA treatment of PA-1 and 2102Ep cells (roughly 22-fold and 12-fold, respectively; Fig. 2a ). We observed a similar response in 833KE cells; however, we did not readily detect retrotransposition in NTera2D1 cells ( Supplementary Fig. 4a , b and data not shown). We saw reactivation of L1-retro-EGFP expression on treatment of PA-1 cells with sodium butyrate and valproic acid, but not on treatment with 5-azacytidine ( Supplementary Fig. 4c ). Controls revealed that TSA treatment reactivated existing L1-retro-EGFP events and did not result in a burst of L1 retrotransposition ( Supplementary Fig. 4d -f). Thus, several ECs accommodate L1 retrotransposition, but the resultant L1-retro-EGFP events undergo efficient silencing.
We also observed efficient silencing in PA-1 cells when the cytomegalovirus immediate-early (CMV) promoter driving EGFP expression was replaced with the mouse phosphoglycerate kinase-1 (pgk) promoter, and when the SV40 polyadenylation signal was removed from the L1 expression construct ( Supplementary Table 1 ) 13, 14 . Similarly, we observed efficient L1-retro-EGFP silencing when the cassette was delivered by a mouse L1 (T GF 21) 15 , a synthetic mouse L1 (L1SM) 16 or a zebrafish LINE-2 element that retrotransposes at a low level in human cells 17 . In each instance, TSA treatment reactivated the silenced L1-retro-EGFP cassette ( Supplementary Table 1 , Supplementary Fig. 4h , i and data not shown). Thus, the establishment of L1-retro-EGFP silencing appears to be independent of viral sequences or sequences within the engineered LINE constructs.
Retroviral insertions can also be efficiently silenced in ECs [18] [19] [20] [21] . To determine whether the kinetics of retroviral and L1-retro-EGFP silencing are similar, we infected PA-1 cells with a human immunodeficiency virus (HIV89.6DENV) or a replication-deficient Moloney murine leukaemia retrovirus carrying an EGFP reporter gene. We then treated the cells with or without TSA seven days post-infection. Flow cytometry revealed that TSA treatment modestly increased the number of EGFPpositive PA-1 cells in the retroviral-based experiments, although the extent of reactivation was not as pronounced as in the L1-retro-EGFP experiments (roughly 2-fold in the human immunodeficiency virus experiment or roughly 3-fold in the Moloney murine leukaemia virus experiment versus more than 20-fold in the L1 experiments; Fig. 2b and Supplementary Table 1 ). Controls demonstrated that transfection of PA-1 or 2102Ep cells with a linearized neomycin or hygromycin expression plasmid readily led to the formation of drug-resistant foci ( Supplementary Fig. 4g and data not shown). Thus, the efficiency of EGFP reporter-gene silencing seems to depend on the mechanism of integration.
We next characterized 36 clonal PA-1 cell lines containing at least one silenced L1-retro-EGFP event (see Supplementary Methods). Thirty-three cell lines exhibited efficient silencing, and we detected EGFP-positive cells only on TSA treatment (for example, pk-5; Fig. 3a ). Three cell lines (for example, pk-87; Supplementary Fig.  5 ) exhibited only modest L1-retro-EGFP silencing, although TSA treatment increased the number of EGFP-positive cells (Supplementary Fig. 5 ). Characterization of nine retrotransposition events revealed that six occurred either within known genes or in genomic regions associated with expressed sequence tags ( Supplementary  Table 2 ), which is consistent with previous studies in cultured cells 3, 5, 8, 12, 13 .
We analysed the pk-5 clonal cell line in greater detail. Southernblot and inverse-PCR (ref.
3) analyses revealed the presence of a single full-length L1-retro-EGFP event on chromosome 12q21.1 ( Fig. 3a, b ; Supplementary Fig. 6a ). Treating pk-5 cells with TSA ( Fig. 3a ; Supplementary Movie), sodium butyrate, or valproic acid ( Supplementary Fig. 6b , see 24-h panels; and data not shown) reactivated the silenced L1-retro-EGFP event. Additional experiments revealed that L1-retro-EGFP reactivation did not require cell division ( Supplementary Fig. 7 ), and that withdrawal of histone deacetylase inhibitors led to a steady decrease in the number of EGFP-positive cells over a 120-h period ( Fig. 3c ; Supplementary Fig. 6b ). Thus, the maintenance of L1-retro-EGFP silencing probably requires the presence of active histone deacetylases. The slower kinetics required to reestablish the silenced state in pk-5 cells may reflect the half-life of the EGFP protein (roughly 20 h) 22 .
To test whether reactivation of L1-retro-EGFP expression is correlated with histone modifications at the L1 integration site, we performed chromatin immunoprecipitation on naive and TSA-treated pk-5 cells, using antibodies diagnostic of transcriptionally active (acetylated histone-H4; H4ac) and transcriptionally repressed (dimethyl histone-H3-Lys9; H3K9me2) chromatin 23 . Quantitative-PCR experiments revealed a roughly 9-fold increase in the number of EGFP sequences precipitated using the H4ac antibody in TSA-treated pk-5 cells when compared to the untreated cell line, and a roughly 7-fold decrease in the number precipitated using the H3K9me2 antibody in TSA-treated pk-5 cells when compared to the untreated cell line (Fig. 3d ). Thus, reactivation of L1-retro-EGFP expression is accompanied by histone modifications, indicating that silencing is principally mediated at the chromatin level.
Previous studies indicated that the silencing of retroviral sequences is attenuated in differentiating cells [19] [20] [21] . To test whether differentiation affects L1-retro-EGFP silencing, we transfected PA-1 cells with pLRE3/mEGFPI. We grew the cells for seven days in standard medium (10% fetal bovine calf serum; FBS) or medium that promotes differentiation (see Supplementary Methods) , and then treated them with or without TSA to assay for L1-retro-EGFP silencing. TSA treatment resulted in similar numbers of EGFP-positive cells whether cells were grown in 10% FBS or in differentiation medium, indicating that the growth medium did not dramatically affect L1 retrotransposition ( Fig. 4a ; Supplementary Fig. 8a, b ). However, we readily detected EGFP-positive cells in differentiation medium without TSA treatment (roughly 10% of cells grown in differentiation medium versus less than 0.3% of cells grown in 10% FBS; Fig. 4a ; Supplementary Fig.  8a, b ). Controls verified that the majority of EGFP-positive PA-1 cells identified in differentiation medium stained negatively for the transcription factor Oct4 and positively for the epithelial cell surface marker Lu5 ( Supplementary Fig. 8c-e ). We obtained similar results from experiments using a human L1 (pJM101/LRE3) 3 or a codonoptimized mouse L1 (pCEPL1SM) 16 containing the mneoI retrotransposition indicator cassette ( Supplementary Figs 3 and 8f ). Thus, L1-retro-reporter-gene silencing is more efficient in ECs than in differentiating cells. 2102Ep cells, which do not differentiate when grown in differentiation medium 24 , consistently exhibited L1-retro-EGFP silencing when experiments were conducted in either 10% FBS or differentiation medium ( Supplementary Fig. 9 ). We next generated a population of silenced L1-retro-EGFP retrotransposition events in PA-1 cells (Fig. 4b) . We grew the EGFP-negative cells in 10% FBS or differentiation medium for seven days in the presence of the reverse transcriptase inhibitor 39-azido-39-deoxythymidine, to repress further L1 retrotransposition 25 . TSA treatment was required to reactivate L1-retro-EGFP expression in both 10% FBS and differentiation medium (Fig. 4b) . Growing the clonal pk-5 cell line in differentiation medium rarely led to EGFP-positive cells (roughly 2% of cells; Supplementary Fig. 10 ). Thus, differentiation, in itself, is not sufficient to efficiently reactivate previously silenced L1-retro-EGFP insertions.
Our study builds on existing literature, suggesting that host mechanisms act to regulate L1 retrotransposition 5, [26] [27] [28] [29] [30] . We propose that L1-retro-EGFP silencing occurs by a two-step process (Fig. 4c) . First, because reporter cassettes delivered by various non-longterminal-repeat retrotransposons are silenced in PA-1 cells, we speculate that nascent L1 complementary DNAs may be targeted by host factors, apparently sequence-independently, to 'initiate' L1-retro-EGFP silencing either during target-site primed reverse transcription or immediately after integration. Second, because the removal of histone deacetylase inhibitors results in the re-establishment of L1retro-EGFP silencing, we propose that histone-modification enzymes (deacetylases) act to maintain silencing, and that silencing in ECs, at least in the short term, does not require methylation of the retrotransposed L1-retro-EGFP cDNA. It remains possible that L1s insert into chromosomal regions that are preferentially silenced in ECs but not in differentiated cells, although such a result lacks precedent and is not supported by the initial characterization of retrotransposition events in PA-1 cells (Supplementary Table 2 ). The silencing of L1retro-EGFP events in ECs that express endogenous L1s may seem paradoxical. However, because 3 out of 36 (roughly 8%) L1-retro-EGFP events in PA-1 cells evaded complete silencing (see Supplementary Fig. 5 ), we suggest that some full-length endogenous L1s are expressed from favourable genomic contexts, and speculate that L1mediated reporter-gene silencing may represent a mechanism for regulating retrotransposition in cells that naturally express human L1s.
We further determined that L1-retro-EGFP silencing is attenuated in differentiating cells, but that differentiation is not sufficient to reactivate a previously silenced L1-retro-EGFP cassette. A similar pattern has been reported for retroviral silencing in pluripotent cells [19] [20] [21] . Thus, we speculate that host factor(s) required for the initiation of L1-retro-EGFP silencing are expressed in multipotent ECs and undergo downregulation during cellular differentiation. Alternatively, a repressor of L1-retro-EGFP silencing could be activated on differentiation. In either case, we have uncovered a novel mechanism that mediates the silencing of engineered L1 retrotransposition events in ECs.
METHODS SUMMARY
Cell culture and plasmid DNA. We grew HeLa and human ECs as described 3,13 . DNA constructs are described in the Supplementary Methods section (see also Supplementary Methods for specific details and references to previously published works). Retrotransposition assays. Cell transfection and L1-retrotransposition assays were performed as described [12] [13] [14] . In some instances, puromycin was added to the medium to select for the episomal L1 expression vector. Where indicated, transfected cells were treated with 500 nM-1 mM trichostatin A (TSA, Sigma), 1 mM valproic acid (VPA, Sigma), 1 mM sodium butyrate (NaB, Sigma) for 14-16 h, or with 25 mM 5-azacytidine (5-Aza, Sigma) for at least 56 h, to assay for the reactivation of L1-retro-EGFP expression. Silencing assays are reported in refs 5 and 8. Treating cells with TSA for longer than 24 h resulted in toxicity; thus, we performed time-course studies to optimize the TSA treatment time for our assays. Southern blot and PCR. We conducted PCR reactions to follow the removal of the intron from the retrotransposition indicator cassette as described 13, 14 . We also conducted Southern blot and inverse PCR as described 3,5,12 . Western blot and immunocytochemistry. We performed western-blot and immunocytochemistry analyses as described 3 . Chromatin immunoprecipitation assays. We performed chromatin immunoprecipitation assays as described 23 . 
